Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Confusion Marks Rollout Of Universal Health Coverage In Indonesia

This article was originally published in PharmAsia News

Executive Summary

Initial confusion on access, eligibility and paperwork greeted the rollout of phased national health insurance for Indonesia that aims to achieve a nationwide footprint before the end of the decade.

You may also be interested in...



Part D vs. Obamacare Roll-Out: The Comparisons Continue

The Part D rollout is not a perfect parallel for the launch of the Affordable Care Act, but comparing their respective “glitches” is now commonplace. Former CMS Administrator Mark McClellan sees important differences—and cautions that the toughest test is still to come.

Mixed Impact From Indonesian Foreign Ownership Changes?

A new economic stimulus package from the Indonesian government that includes allowing up to 100% foreign ownership in the pharmaceutical and health sectors has been welcomed by the multinational industry.

Indonesian Insurance Scheme ‘Not Sharia-Compliant’, Muslim Body Says

An edict by a top Muslim council in Indonesia that the country’s national health insurance does not follow Islamic sharia law principles has sparked debate in the world’s most populous Muslim-majority country.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC085706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel